采用NovoSorb® BTM治疗大面积烧伤患者的临床结局与资源利用
这项回顾性队列研究纳入皇家布里斯班妇女医院成人烧伤病房收治的烧伤面积至少40% TBSA且急性期存活的患者,比较2017年7月至2022年6月使用BTM治疗的患者与2013年1月至2017年6月使用尸体异体皮作为临时全厚创面覆盖的相似损伤患者。结果显示两组在手术次数、异体皮使用、住院和ICU住院时间及血制品使用方面相似,BTM组手术室总时间显著更少(中位1361.5分钟 vs 1768分钟,P=0.044)。
要点
- BTM组手术室总时间显著少于无BTM组(中位1361.5分钟 vs 1768分钟,P=0.044)。
- 两组手术次数、异体皮使用、住院和ICU住院时间及血制品使用相似。
- 校正TBSA的多变量线性回归模型支持未校正模型的结果。
核心结论
- 在至少40% TBSA烧伤患者中,使用BTM治疗与BTM引入前使用异体皮治疗的患者在资源利用和临床结局方面相似。
- BTM组手术室总时间显著更少,手术次数、异体皮使用和ICU住院时间无差异。
研究设计与样本
- 回顾性队列研究,纳入皇家布里斯班妇女医院成人烧伤病房收治的烧伤至少40% TBSA且急性期存活的患者。
- BTM组为2017年7月至2022年6月接受BTM治疗的患者,对照组为2013年1月至2017年6月使用尸体异体皮作为临时全厚创面覆盖的相似损伤患者。
- 共纳入55例患者(78%男性),其中22例接受BTM治疗。
主要发现
- 两组年龄、性别和TBSA无显著差异。
- 1例患者因感染移除一半BTM并替换为异体皮。
- BTM组手术室总时间显著更少(中位1361.5分钟 vs 1768分钟,P=0.044)。
- 两组手术次数、异体皮使用、住院和ICU住院时间及血制品使用相似。
- 校正TBSA的多变量线性回归模型支持未校正模型的结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with major burns can undergo temporary coverage while skin graft donor sites heal, where dermal templates have an emerging role. The aim of this study was to evaluate the clinical outcomes and resource utilisation in patients with major burns treated with a bilayer biodegradable synthetic matrix (NovoSorb BTM). METHOD: This retrospective cohort study included patients admitted to the Royal Brisbane and Women's Hospital Adult Burn Unit with burns to at least 40 % TBSA who survived their acute admission. Patients treated from July 2017 to June 2022 with BTM were compared with patients with similar injuries treated using cadaveric allograft as temporising full thickness wound coverage between January 2013 and June 2017. Outcomes measures included number of operations, total operative time, hospital and intensive care unit (ICU) length of stay (LOS), cadaveric allograft and BTM use, and blood product use. Unadjusted comparisons were made with Wilcoxon Rank-Sum tests and Fisher's exact tests. Multivariate linear regression was used to adjust for the effect of TBSA on each outcome. RESULTS: Fifty-five patients were included (78 % male), 22 of whom were treated with BTM. We found no significant differences in age, sex, or TBSA between groups. One patient had half of the BTM removed due to infection and replaced with allograft. Patients treated with BTM had significantly less operative theatre time (median 1361.5 min [BTM] vs 1768 min [no BTM], P = 0.044). Number of operations, allograft use, hospital and ICU LOS, and blood product use were similar between groups. Adjusted models accounting for TBSA supported unadjusted models. CONCLUSION: Resource utilisation and clinical outcomes were similar in patients with at least 40 % TBSA treated with BTM and those who were treated with allograft before the introduction of BTM. Patients treated with BTM had significantly less total operative time and no difference in number of operations, allograft use and ICU LOS.
引用
- Betar N, Maher D, Wheatley L, et al. Clinical outcomes and resource utilisation in patients with major burns treated with NovoSorb® BTM. Burns. 2023. PMID: 37344307. doi:10.1016/j.burns.2023.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。